News - Amgen

Filter

Current filters:

Amgen

Popular Filters

10 to 34 of 145 results

Advanced melanoma collaboration for Amgen and Merck & Co

Advanced melanoma collaboration for Amgen and Merck & Co

05-02-2014

World leading independent biotech firm Amgen and US pharma giant Merck & Co have entered into an agreement…

AmgenBiotechnologyMerck & CoMK-3475OncologyResearchtalimogene laherparepvec

Systemic psoriasis market forecast to reach $10.4 billion by 2020

05-02-2014

The systemic psoriasis treatment market value in the eight major countries (8MM) - the USA, Canada, France,…

AmgenapremilastBiotechnologybrodalumabCelgeneDermatologicalsEli LillyMarkets & MarketingNovartisPfizersecukinumabXeljanz

Amgen announces top-line results from Phase III trial of evolocumab

Amgen announces top-line results from Phase III trial of evolocumab

29-01-2014

USA-based Amgen announced that the Phase III LAPLACE-2 trial evaluating evolocumab (AMG 145) in combination…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

Amgen again tops analysts’ forecasts as profits rise 30%

Amgen again tops analysts’ forecasts as profits rise 30%

29-01-2014

Amgen, the world’s largest independent biotech firm, for the fifth reporting quarter beat analysts’…

AmgenBiotechnologyFinancial

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

Amgen’s evolocumab beats Zetia in Ph III GAUSS-2 trial for cholesterol reduction

24-01-2014

USA-based Amgen yesterday revealed positive results from the Phase III GAUSS-2 (Goal Achievement After…

AmgenBiotechnologyCardio-vascularevolocumabResearchZetia

Amgen and Illumina to develop companion diagnostic for Vectibix

Amgen and Illumina to develop companion diagnostic for Vectibix

16-01-2014

USA-based Illumina has entered into an agreement with Amgen to develop and commercialize a multigene,…

AmgenBiotechnologyIlluminaOncologyResearchVectibix

Amgen launches collaboration with academia for IBD drug development

15-01-2014

US biotech firm Amgen says it has launched a strategic collaboration with Massachusetts General Hospital…

AmgenBiotechnologyGastro-intestinalsMarkets & MarketingResearch

Amgen and UCB’s romosozumab shows significant increase in BMD

Amgen and UCB’s romosozumab shows significant increase in BMD

02-01-2014

US biotech firm Amgen and partner UCB of Belgium have announced positive results from a Phase II trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyForteoFosamaxResearchromosozumabUCB

Amgen reports positive results from Phase III trial of evolocumab for high cholesterol

Amgen reports positive results from Phase III trial of evolocumab for high cholesterol

18-12-2013

USA-based biotech company Amgen (Nasdaq: AMGN) has revealed positive top-line Phase III results for its…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Avesthagen in deal with Elpen for biosimilar Aranesp in parts of Europe

21-11-2013

Avesthagen Pharma AG, a unit of India’s Avesthagen Ltd, has signed an agreement with Greek life sciences…

AmgenAranespAvdespAvesthagenBiosimilarsElpen PharmaceuticalsEuropeMarkets & MarketingNephrology and Hepatology

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

Amgen’s PCSK9 inhibitor evolocumab reduces cholesterol in Phase II study

20-11-2013

USA-based biotech firm Amgen (Nasdaq: AMGN) has said its investigational PCSK9 inhibitor evolocumab helped…

AmgenBiotechnologyCardio-vascularevolocumabNorth AmericaResearchUSA

Favorable OS Ph III results with Amgen’s talimogene laherparepvec in melanoma patients

Favorable OS Ph III results with Amgen’s talimogene laherparepvec in melanoma patients

20-11-2013

USA-based Amgen has presented positive interim overall survival results from a pivotal Phase III trial…

AmgenBiotechnologyOncologyResearchtalimogene laherparepvec

Stada Arz expands biosimilars range, in-licensing Grastofil from Apotex

Stada Arz expands biosimilars range, in-licensing Grastofil from Apotex

30-10-2013

German generic and branded drugmaker Stada Arzneimittel says it has strengthened its activities in the…

AmgenApotexBiosimilarsEuropeGrastofilHematologyLicensingNeupogenSTADA Arzneimittel

Amgen reports 24% rise in income with 11% growth in sales

Amgen reports 24% rise in income with 11% growth in sales

23-10-2013

Amgen has announced its third quarter results with an 11% growth in sales. Its net income was up 24%…

AmgenFinancialNorth AmericaPharmaceutical

Kissei and JCR conclude accord on biosimilar Aranesp

01-10-2013

Kissei Pharmaceutical and JCR Pharmaceuticals have announced the conclusion of a collaborative R&D agreement…

AmgenAranespAsia-PacificBiosimilarsGenericsJCR PharmaceuticalsKissei PharmaceuticalOncologyResearch

Amgen to open China R&D Center at ShanghaiTech

28-09-2013

Amgen and ShanghaiTech University have entered into a memorandum of understanding to form a strategic…

AmgenAsia-PacificBiotechnologyResearch

SOBI restructures Kineret and Kepivance deals

09-09-2013

Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

Baxter and Coherus in up to $246 million deal for biosimilar etanercept

04-09-2013

US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

10 to 34 of 145 results

Company Spotlight

Fibrotech

Fibrotech

Back to top